BTEE:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (USD)

ETF | Others |

Last Closing

USD 6.308

Change

0.00 (0.00)%

Market Cap

USD 0.52B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-11 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-16.80 (-6.21%)

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

-0.95 (-1.52%)

USD 292,109.19B
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

+295.00 (+3.45%)

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

+0.25 (+0.14%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+14.20 (+1.26%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.02 (-0.14%)

USD 592.18B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.04 (-0.20%)

USD 592.18B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+2.75 (+0.14%)

USD 330.91B

ETFs Containing BTEE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.17% 24% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.17% 22% F 32% F
Trailing 12 Months  
Capital Gain 3.50% 32% F 44% F
Dividend Return 0.23% 39% F 67% D+
Total Return 3.74% 30% F 43% F
Trailing 5 Years  
Capital Gain 36.55% 51% F 63% D
Dividend Return 0.69% 25% F 16% F
Total Return 37.24% 49% F 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 6.42% 59% D- 64% D
Dividend Return 6.53% 59% D- 63% D
Total Return N/A 100% F 100% F
Risk Return Profile  
Volatility (Standard Deviation) 19.72% 36% F 50% F
Risk Adjusted Return 33.11% 55% F 67% D+
Market Capitalization 0.52B 71% C- 61% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.